Content Topic: Innovation

Innovation

Immunology Q&A: Experts discuss how science is advancing disease research

Merck R&D teams are exploring how emerging therapies and precision medicine are shaping the future of immune-mediated disease research

April 30, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

With a deep and growing understanding of human biology, there’s been an emergence of innovative medicines and new modalities that aim to change the way researchers approach treatment for immune-mediated inflammatory diseases.  

Here at Merck, we’re advancing our growing capabilities in immunology with a talented team of scientists and clinical researchers as we aim to advance patient care. We sat down with two immunology experts from Merck Research Laboratories (MRL) to find out how their teams are fostering innovations that have the potential to help people with autoimmune diseases. 

Over the past decade, what scientific developments have most shaped how you and your team discover new targets for immune-mediated diseases? 

Dr. Marc Levesque, vice president, immunology discovery and Cambridge site head, MRL: The past decade has been transformative for the field of immunology research. Technologies like oral macrocyclic peptides and CAR-T (chimeric antigen receptor T-cell) therapies have opened new possibilities in research. 

Critically, the integration of patient-derived data into early-stage research has allowed us to evaluate disease mechanisms with greater accuracy. Integrating these new tools not only enhances our understanding of immune-mediated diseases but also enables the discovery of novel targets and biomarkers that could lead to more precise treatments. 

Which advances have most changed the way we approach immune-mediated diseases — and where do gaps remain? 

Dr. Aileen Pangan, vice president and therapeutic area head, immunology clinical research, MRL: Our understanding of disease mechanisms has grown dramatically, leading to the identification of new therapeutic targets. These advances have improved treatment outcomes for many patients. Yet, significant gaps remain, particularly in achieving and maintaining clinical remission for patients. 

One of the reasons lies in the fact that treatment of these patients still involves a trial-and-error approach. We’re investing in efforts to bring precision medicine to immunology. If we could identify the right therapy for each patient, we could help manage disease manifestations sooner and potentially improve long-term outcomes.

How are these advances shaping Merck’s R&D strategy? 

Levesque: Our goal is to alleviate the burden of immune-mediated diseases by discovering and developing innovative, targeted therapies. Our strategy involves tackling multiple pathways involved in these complex diseases. 

For example, promising areas of research include bispecific antibodies which can be used to target more than one disease mechanism at a time and new modalities that enable oral administration.

What roles do artificial intelligence (AI) and data analytics play in the evolution of immunology research? 

Levesque: AI and data analytics are accelerating how we identify new drug targets and tailor therapies. These tools allow us to process vast amounts of biological data quickly, revealing patterns and insights that would be difficult to detect otherwise. This can help support the development of precision medicine, with the goal of tailoring to the unique genetic and biological makeup of each patient, while also speeding up the discovery process for new drug targets. AI also facilitates the design of drugs and their testing in pre-clinical studies. 

four scientists working in our Boston lab

How does the patient experience factor into your approach to clinical research? 

Pangan: Understanding the unique patient experience for each autoimmune disorder we work on can help in the development of innovative therapies that more directly address patient needs. Currently, many patients will cycle through multiple treatments before finding an option that works for them, while others experience a delay in initiating advanced therapies.  

Our approach to research and development in this space takes into account the challenges and barriers patients experience when trying to achieve their treatment goals, which may differ depending on the autoimmune or immune-mediated inflammatory disease. These considerations inform how we pursue modalities and targets that have the potential to provide more options and support a more personalized care plan. By doing so, we aim to help more patients reach their treatment goals.

In your opinion, as we look five to 10 years ahead, what scientific advancements could fundamentally change how we treat immune-mediated inflammatory diseases? 

Levesque: In the coming years, I believe scientific advancements may lead to improvements in durable remission. Personalized medicine based on individual genetic profiles and disease characteristics has the potential to fundamentally change how physicians and care teams approach treatment plans for patients. It also has the potential to shorten the time to symptom resolution by helping to select the most suitable therapy for patients. Overall, our goal is to help address patient challenges and provide more treatment options.  

Learn more about our research and commitment to immunology. 

Innovation

Our Q1 2026 financial results

April 30, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Scientist in lab

Merck’s (NYSE: MRK) Q1 2026 results reflect continued strength in oncology and animal health, plus increasing contributions from launches. Our company announced Q1 worldwide sales of $16.3 billion.

“We are moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas,” said Rob Davis, chairman and CEO. “During the first quarter, we continued to strengthen our pipeline with science-led business development, including our planned acquisition of Terns. We also achieved several important milestones, such as our most recent approval in HIV, marking a new chapter in our research and longstanding commitment to people living with HIV. I am pleased with our progress and excited for what’s ahead, as we enter a particularly robust period of Phase 3 data readouts and deliver on the promise of our pipeline for patients.”

Merck anticipates full-year 2026 worldwide sales to be between $65.8 billion and $67.0 billion.

Take a look at the infographic below for more details on Q1 2026 results.

Listen to the earnings call

Read the press release

Q1 2026 Earnings Infographic

Download the infographic

Innovation

How Merck scientists are driving next-generation cancer research

Our scientists are accelerating research by looking to improve anti-tumor immune response, targeting specific cancer cells and helping inhibit cancer growth

April 20, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease — scientists have classified hundreds of types and found a myriad of genetic drivers underlying them. This means, just as cancer isn’t one disease, there cannot be just one way to treat all cancers.

“We’ve witnessed dramatic progress in how we treat a wide range of cancers, and our work at Merck has been foundational in how we treat metastatic disease, or cancer that has spread.”

  • Dr. Jane Healy
    Vice president and head of oncology early development, Merck Research Laboratories

“This is just the tip of the iceberg. These advancements are helping to fuel the next generation of discoveries and drive progress in the way we care for people with all stages of cancer. We must push research forward that supports early discoveries and novel innovations to advance the future of cancer research,” Healy said.

Driving research toward treating certain cancers earlier

With the ultimate goal of providing patients with the greatest chance for survival, our researchers are building a broad clinical development program focused on treating certain cancers at earlier stages.

“Expanding our research efforts into earlier stages of disease remains a top priority,” said Healy. “We’re pursuing research where we have the greatest potential to make a significant impact in helping reduce the risk of recurrence and improving survival.”

A robust pipeline of diverse approaches to advanced and earlier stages of cancer

In addition to driving research in earlier stages of cancer, Healy and her colleagues are investigating multiple mechanisms and modalities that may have the potential to address cancer in innovative ways. Through our own research and external collaborations, we’ve developed a robust pipeline that encompasses diverse approaches to treating advanced and earlier stages of cancer across more than 20 novel mechanisms, including:

  • Boosting anti-tumor immune responses: Learnings from recent advancements in cancer care have informed a more focused approach to research. Now, we’re investigating foundational cancer treatments combined with negative immune regulators that play different roles in adjusting the immune response.

    We’re also exploring individualized neoantigen therapies, a growing area of research focused on sharpening the immune response against a person’s own tumor by developing a therapy unique to their tumor’s mutation.
  • Tissue-specific targeting of chemotherapy to increase cancer cell sensitivity to immune responses: While chemotherapy remains an important treatment option, our scientists are exploring how antibody-drug conjugates (ADCs), with novel chemotherapy-like payloads, can be used as a more targeted approach to deliver chemotherapy.

    Similarly, we’re pursuing research that enhances the ability of T cells to recognize and attack tumors.
  • Impacting pathways that can drive cancer growth: We’ve identified opportunities for the direct targeting of cancer cell vulnerabilities and transcription factors that were previously considered untreatable. By designing therapeutic candidates that inhibit or degrade proteins and genes implicated in cancer pathways, we’re evaluating new ways to help address rare and difficult-to-treat cancers that currently have limited treatment options.

"We're committed to investing in novel research where scientific opportunity and medical need converge. "

— Jane Healy

“These key areas of research are the cornerstones of our broad and diverse pipeline, with more than 2,800 trials that will evaluate patients in combination regimens. We remain dedicated to discovering new ways to fight this disease and optimizing existing approaches — all while continuing to lead in supporting the next generation of cancer research,” said Healy.

Gloved hand handling a small laboratory device labeled

Learn more about our oncology pipeline

View pipeline
Innovation

Rob Davis on strengthening our pipeline through business development

Merck’s chairman and CEO spoke with the Financial Times about dealmaking, pipeline expansion and delivering for patients

April 14, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

In a recent interview with the Financial Times, Merck Chairman and CEO Rob Davis shared how, when it comes to investing in our pipeline of innovative medicines and vaccines, we always put patients first.

This mindset drives our approach to advancing the best internal and external science where we see science and value align and is fueling the evolution of the strongest and deepest pipeline in our company’s history.

The outlet noted that Davis has led our company through a period of significant dealmaking, with one outcome being that we currently have 22 medicines in the final stages of clinical trials compared to 15 in 2023. “We have as rich a Phase 1, Phase 2 and Phase 3 pipeline as we’ve ever had in this company,” Davis said. He also expressed the importance of moving with focus and urgency, as well as discipline, to rapidly progress the next wave of innovation. “The earlier we bet, the more conviction my scientists have to have,” he said.

As we continue to complement our internal innovation and discovery efforts with patient-focused business development to drive impact for all who depend on us, we remain committed to delivering on our purpose of using the power of leading-edge science to save and improve lives around the world.

Innovation

Expert Q&A: The role of real-world evidence in lung cancer detection

Shuvayu Sen, Ph.D., shared how our real-world evidence research uses data to analyze patient journeys and risk prediction models for early lung cancer detection

March 23, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

In the fight against lung cancer, early detection can be critical. While some countries have previously rolled out national lung cancer screening programs, in many cases, participation was low. This reality is one of the drivers behind Mission Lung Cancer, our collective effort to break down the barriers that stand in the way of early detection of lung cancer. 

At the heart of our commitment to early lung cancer detection is one of our powerful contributions: scientific insights. Our real-world evidence (RWE) research uses patient-level data to analyze patient journeys and risk prediction models. This enables us to better understand diagnostic pathways and identify opportunities that may help facilitate early detection and diagnosis of lung cancer. 

We spoke with Shuvayu Sen, Ph.D., vice president and head of oncology value and implementation outcomes research, about the importance of using RWE.

What is RWE and why does it matter? 

Sen: RWE is generated through the analysis of real-world data or health information routinely collected from sources such as electronic health records (EHR), registries and insurance claims. Alongside data from clinical trials, real-world data matters because it may provide contextual insights that are not possible in a controlled setting.

How is your team using RWE in lung cancer research?

Sen: Our applicable areas of research include continuing to address smoking as the leading risk factor for lung cancer while identifying additional contributing risk factors — pinpointing moments to engage at-risk individuals and building explainable risk prediction models, including for non-small cell lung cancer. Our research on the patient journey can help show where delays in care may occur, such as low screening uptake, missed follow-ups on imaging or coordination gaps between care teams.

What have you learned from RWE in lung cancer?

Photo of Merck colleagues Shuvayu Sen and Melissa Santorelli walking in the office
Sen (left) with colleague Melissa Santorelli, Ph.D., MPH, at our global headquarters.

Sen: As part of our analysis of one institution’s EHR database, we identified underutilization of low-dose computed tomography (CT) scans as an unmet need in the diagnostic pathway. Our research also showed potential for electronic medical record data to help identify patients who may be at risk of developing lung cancer. Looking ahead, we aim to explore options that could support earlier detection by leveraging this data. These insights point to potentially meaningful opportunities across the oncology ecosystem and beyond.

How else are we helping to advance research in this space?

Sen: We believe it’s critical to advance this work through research outside our company, as shared insights and investigator-led research are equally essential to accelerating innovation. That’s why we expanded our Merck Investigator Studies Program (MISP) to support independent research.

The MISP program evaluates tools and methods for lung cancer risk assessment and explores new technologies, like artificial intelligence (AI) and digital diagnostics, with the goal of improving early detection and diagnosis of lung cancer.

Together, our real-world evidence and MISP-supported research have the potential to reshape how and when lung cancer may be detected.

Learn more about Mission Lung Cancer.

Innovation

Our AI model KERMT is helping to advance drug discovery

Our scientists harness AI and machine learning in small molecule lead optimization

March 19, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

illustration of people in lab coats looks at shapes and objects floating

In the lead optimization phase, scientists fine-tune early molecules in the hopes of finding a molecule that might one day become a medicine.

Traditionally, this stage takes months, and most drug candidates never make it to clinical testing. But advancements in artificial intelligence and machine learning (AI/ML), including our new AI foundation model KERMT, could help change that.

What is KERMT and how is it transforming small molecule research?

Developed in collaboration with Nvidia, KERMT, pronounced “Kermit” and short for Kinetic GROVER Multi-Task, is a deep-learning computer model trained on more than 11 million molecules. It learns from patterns in vast amounts of chemical data with the goal of helping scientists better predict how a molecule will behave in the body, potentially spotting issues much earlier and reducing the need for months of lab work.

KERMT isn’t just helping our researchers; as an open-source model, its code is available to the whole scientific community.

How AI models can impact drug development timelines

In a recent interview with Healthcare Brew, Senior Director of Data Science Alan Cheng said AI is already “speeding up the early stages of drug development dramatically.”

“AI is sometimes cutting timelines by 30% or more, improving drug candidate quality and reducing costs,” Cheng said. “This is a very meaningful acceleration. While clinical trials remain lengthy, our models are enabling faster identification of disease targets and optimized compounds, which should increase probability of success and shorten preclinical phases.”

Open-source AI for the scientific community

AI/ML is evolving at an incredible pace: access to relevant data is growing, computing power is expanding and deep-learning algorithms are rapidly improving. Advances like KERMT can give teams a powerful new way to make better informed decisions and focus their time on the most promising drug candidates.

These changes have the potential to create unprecedented opportunities to speed and strengthen the discovery of new drugs — with the goal of bringing safer, more effective medicines to patients faster.

KERMT is available on Nvidia accelerated computing and software, including platforms like Nvidia BioNeMo and Clara Open Models.

Watch to learn more about how Merck is using AI/ML for small molecule lead optimization 

Innovation

We’re teaming up with Eisai to help fight cancer

How we're leveraging each other’s unique strengths to help advance cancer research

March 12, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

scientists wearing masks working in a lab

Combining two ambitious research teams to form a united front to help people with cancer

It’s sometimes said that the whole is greater than the sum of its parts. That’s why in 2018 we teamed up with Eisai, a global pharmaceutical company headquartered in Japan, to work together to advance cancer research.

“Combining Merck’s leadership in oncology with Eisai’s strengths in small molecules allows us to advance combination approaches that have the potential to help more people living with challenging cancers,” said Dr. Gregory Lubiniecki, vice president, global clinical development, Merck Research Laboratories.

“There’s still an unmet need for many patients with cancer. These patients and their families are in need of more treatment options, and this remains at the forefront of our collaborative efforts.”

  • Dr. Takashi Owa
    Head of external innovation, Deep Human Biology Learning (DHBL), Eisai Co., Ltd.

Together, we’re striving to drive cancer science forward, and this shared vision has led to multiple clinical trials investigating the companies’ combination treatment options in various tumor types.

Through this comprehensive approach, we’ve been expanding our clinical research to help as many cancer patients as possible.

Why did you decide to go into oncology research?

“My decision was very personal,” said Owa. “At the age of six, my grandmother passed away from gastric cancer. I couldn’t fully process what had happened to her at that young age. It wasn’t until I entered junior high school that I began to understand the toll cancer had taken on her, which motivated me to learn about cancer and find my passion in cancer research.”

Lubiniecki’s experience was also very personal.

“Watching my mother recover from breast cancer while I was in high school exposed me to the challenges patients face when battling cancer. These experiences inspired me to ultimately pursue oncology,” he said. “Oncology clinical research offers an opportunity to impact the practice of medicine greatly.”

Looking to the future

“I’m proud of what we’ve been able to accomplish together in our pursuit to investigate additional options for patients across a broad range of cancer types through our robust clinical research,” said Lubiniecki.

Owa is optimistic about the progress the two teams have made together. “We’ve already seen encouraging anti-tumor activity in several difficult-to-treat cancers, which has led to multiple milestones to date,” he said. “As we continue to enhance our knowledge and scientific evidence through our ongoing clinical research efforts, together, we aim to give patients and their families hope.”

Lubiniecki believes that collaborations are important to continuing to advance cancer research and improve the outcomes of people with cancer.

Dr. Greg Lubiniecki smiling

“A collaborative approach is key to advancing science and making strides in drug discovery and development.”

  • Dr. Gregory Lubiniecki
    Vice president, global clinical development, Merck Research Laboratories

“Working with others driven by the same patient-centric goals can yield innovations and is imperative to continued progress in improving patient care,” said Lubiniecki. “I’m thrilled to be a part of this collaboration as we continue to advance and expand our clinical research.”

Innovation

How wearable technology powers patient-focused drug development

Our scientists are exploring the use of sensor-based technologies and digital clinical measures to improve disease understanding

February 10, 2026

Share this article

Sensor-based digital technologies like smartwatches and other wearables have surged in popularity in recent years. People are easily and conveniently tracking physical activity, sleep and other health-related data — including information that’s helpful for scientists developing new medicines.

At Merck, scientists in our digital clinical measures group are using these sensor-based tools in clinical trials to collect objective measurements which were previously difficult or impossible to obtain. Now, measurements from patients outside the clinic, including at home and work, can provide data that’s more reflective of their everyday lives — deepening our understanding of disease and enabling more efficient and patient-centric drug development.

What are digital clinical measures, and why do we use them?

Digital clinical measures are specific, objective measures of biology, health, behavior or treatment response that are generated via sensor signals from digital technologies processed with algorithms. These measures can be derived from data collected during active task-based assessments, such as timed walk or hand-turning tests performed with wearable sensors, or through passive monitoring, where data are captured continuously as part of everyday activities like walking or sleeping.

Unlike some traditional clinical study endpoints that require lengthy in-clinic exams or patients or caregivers to remember symptoms over days or weeks, sensor-based technologies can objectively and remotely track metrics of health, behavior and treatment response over time. They can also provide more precise measures compared to traditional clinical rating scales.

“Digital clinical measures can augment traditional study endpoints and allow us to collect richer, more frequent data that better reflect how patients live and function day to day.”

  • Marissa Dockendorf, Ph.D.
    Head of digital clinical measures

“In addition to using digital health technologies — or DHTs — to enhance the data we capture in clinical trials, we’re focused on developing more objective and precise measures from these technologies,” added Dockendorf. “These advancements can enable us to understand more quickly, or with fewer clinical trial participants, whether our drug candidates are working, which ultimately can support our ability to deliver medicines to patients faster.”

Collaborating to advance the field of digital measures

We’re working with partners including the Critical Path for Parkinson’s Consortia, the Digital Medicine Society, the University of Oxford and Koneksa Health to advance development of digital clinical measures. These collaborations focus on furthering the digital endpoint field as well as identifying promising digital measures that may improve how we assess disease progression in patients with Parkinson’s disease and, potentially, how we evaluate the efficacy of investigational therapies.

“Digital endpoints hold tremendous promise to transform how we measure and understand health in clinical research,” said Dockendorf. “To fully realize that promise, collaboration is essential as we lay the important groundwork needed to develop measures that are valid, reliable and capable of making a meaningful impact in drug development.”

Digital clinical measures in action in Parkinson's disease

Our researchers are exploring the use of digital health technologies to measure motor function in clinical trials for Parkinson’s disease. Wearable sensor arrays — devices equipped with multiple sensors worn on the body to capture comprehensive data — can provide a wide range of motor function measures, such as gait and turn speed. Collecting data from these technologies over time may provide a clearer understanding of how motor function changes over time and with treatment as compared to traditional endpoints based on categorical rating scales.

Innovation

Our Q4 and full-year 2025 financial results

February 3, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Merck’s (NYSE: MRK) Q4 and full-year 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q4 worldwide sales of $16.4 billion. Full-year 2025 worldwide sales were $65.0 billion.

“In 2025, we continued to advance leading-edge science to deliver transformative medicines and vaccines that are improving health outcomes for patients around the world,” said Rob Davis, chairman and CEO. “Our business benefited from demand for our innovative portfolio, including for KEYTRUDA, increasing contributions from new launches in cardiometabolic and respiratory as well as vaccines, and strong performance of Animal Health. The transformation of our portfolio, bolstered by the acquisitions of Verona Pharma and Cidara Therapeutics, is well underway, and momentum is building as we continue to execute on our strategy. Our progress positions us to continue delivering on our purpose for patients and creating durable value for shareholders.”

Merck anticipates full-year 2026 worldwide sales to be between $65.5 billion and $67.0 billion.

Listen to the sales and earnings call

Read the press release

4Q and full year financial highlights for Merck

Download infographic

Innovation

5 ways we’re transforming artificial intelligence into impact

We’re applying AI across our company to help us work smarter and faster so we can reach patients sooner

January 9, 2026

Share this article

Facebook icon

.st0{fill:#00857C;} X icon

Linkedin icon

Email icon

Computer showing the text:

At Merck, we’re in the business of knowledge, insights and innovation — rooted in intelligence.

Today, artificial intelligence (AI) — or what could also be “automated”, “accelerated” or “augmented” intelligence — lies not only in software and computer systems, but in the data, development and delivery of these intelligent tools to achieve better outcomes for patients.

Here are five ways we’re using AI to drive our purpose of saving and improving lives around the world.

01.

Accelerating the discovery of new medicines

Drug discovery remains an endeavor where only about 1 in 10 drug candidates that enter clinical trials ultimately receive regulatory approval. We’re working to change that by enabling scientists to use AI and machine learning (ML) foundation models to enhance and build upon their existing approaches to drug design before experimental testing and clinical trials.

We recently developed two foundation models which uncover patterns in disease to find better drug targets, allow faster molecular design and rapidly test small molecules, including cyclic peptides, for efficacy and toxicity before going into the clinic.

By unlocking patterns within vast datasets, these AI models enable our scientists to accelerate the discovery of leading therapeutic candidates —  a process that normally takes 10 years — allowing us to potentially get therapies to patients faster without compromising scientific rigor.

illustration of cup

02.

Optimizing clinical trials

Enrolling people in clinical trials and keeping them engaged once they’ve signed up remains a significant challenge across our industry, with approximately 20% of activated sites failing to enroll a single participant. We’re addressing this by using AI to help improve site selection, patient matching and retention. For example, predictive models can flag patients at higher risk of dropping out, enabling targeted interventions that improve retention and keep trials on track.

03.

Automating workflows to improve productivity

Our enterprise-wide training program helps employees understand the latest digital technology, including generative and agentic AI, and learn how to use it responsibly. Our proprietary AI platform — which more than 80% of our workforce uses — applies large language models to enable employees to automate, simplify and digitize processes that historically took more time, freeing us up to prioritize more impactful work.

Illustration of people looking at workflow chart

04.

Modernizing manufacturing

Generative AI helps protect our supply chain when potentially disruptive events like natural disasters or port delays occur. Our systems can produce event-based risk assessments in under 30 minutes — allowing us to quickly see which products and sites are affected and act to avoid or reduce shortages and delays.

In vaccine manufacturing, we’re using computer vision — another form of AI — to inspect vials and syringes for defects. This results in less waste, lower costs and higher production speed.

05.

Streamlining education and engagement with health care providers

We’re using AI to streamline information for providers and patients to ensure we deliver the right details to the right people when it matters most.

We’ve embedded AI across the content life cycle — from conception through medical, legal and regulatory review — so that we can organize messages more intelligently. The result: higher quality, personalized content that gets to health care providers faster.

Supporting this is our generative AI-powered chatbot for our field representatives. It summarizes relevant insights and helps us respond in real time to provider needs.

It all starts with data

Data powers AI. We have a vast repository of proprietary and secure data, but for it to be usable, it must first be structured and organized.

We’re continuously working to create a frictionless data flow so AI can reliably and accurately drive faster, more targeted and personalized outcomes.

Data is critical to our business strategy and to our pipeline. When our data is high-quality, well-manicured and organized to support powerful insights, we can make more accurate and intelligent predictions — and move faster to deliver the medicines and vaccines patients are waiting for.

Read more about how we’re using data science, AI and machine learning.

Related links

toddler smiling while female doctor listens to his heart with a stethoscope

What we do

We use the power of leading-edge science to save and improve lives around the world.
scientist working in a lab

Research

We believe research is the will to conquer the impossible and that science will lead the way.

How we invent

Our teams of scientists bring together diverse expertise and background, combined with cutting-edge technologies, to help discover the next scientific breakthrough for patients.